Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients

European Psychiatry

Volumn 24, Issue 7, 2009, Pages 456-463

  Clark, D ^a   Skrobot, O A ^a   Adebiyi, I ^b   Susce, M T ^c   de Leon, J ^c   Blakemore, AI F ^b   Arranz, M J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Eastern State Hospital   (United States)

Author keywords

Antipsychotics; APOE; Cardiovascular disease; Obesity; Schizophrenia

Indexed keywords

APOLIPOPROTEIN E; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DYSLIPIDEMIA; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEINS E; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTENSION; OBESITY; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA;

EID: 70350060193     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.03.003     Document Type: Article

References (28)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
2. Arranz M.J., and de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12 (2007) 707-747
3. Bennet A.M., Di Angelantonio E., Ye Z., Wensley F., Dahlin A., Ahlbom A., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298 (2007) 1300-1311
4. de Leon J., Susce M.T., Pan R.M., Koch W.H., and Wedlund P.J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 25 (2005) 448-456
5. Dean B., Laws S.M., Hone E., Taddei K., Scarr E., Thomas E.A., et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 54 (2003) 616-622
6. Digney A., Keriakous D., Scarr E., Thomas E., and Dean B. Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry 57 (2005) 711-715
7. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., and Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155 (2002) 487-495
8. Gottlieb D.J., DeStefano A.L., Foley D.J., Mignot E., Redline S., Givelber R.J., et al. Apo-E epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Neurology 63 (2004) 664-668
9. Halford J., Mazeika G., Slifer S., Speer M., Saunders A.M., Strittmatter W.J., et al. Apo-E2 allele increased in tardive dyskinesia. Mov Disord 21 (2006) 540-542
10. Hong C.J., Yu Y.W., Lin C.H., Song H.L., Lai H.C., Yang K.H., et al. Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology (2000) 172-174
11. Kalina A., Szalai C., Prohaszka Z., Reiber I., and Csaszar A. Association of plasma lipid levels with apolipoprotein E polymorphism in Type 2 diabetes. Diabetes Res Clin Pract 56 (2002) 63-68
12. Kampman O., Anttila S., Illi A., Mattila K.M., Rontu R., Leinonen E., et al. Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet 49 (2004) 355-359
13. Long J.R., Liu P.Y., Liu Y.J., Lu Y., Xiong D.H., Elze L., et al. Apo-E and TGF-beta1 genes are associated with obesity phenotypes. J Med Genet 40 (2003) 918-924
14. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1 (2000) 507-537
15. Martins I.J., Hone E., Foster J.K., Sunram-Lea S.I., Gnjec A., Fuller S.J., et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11 (2006) 721-736
16. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 Suppl. 4 (2007) 8-13
17. Nieminen T., Kahonen M., Viiri L.E., Gronroos P., and Lehtimaki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 9 (2008) 1475-1486
18. Osby U., Correia N., Brandt L., Ekbom A., and Sparen P. Mortality and causes of death in schizophrenia in Stockholm county. Sweden. Schizophr Res 45 (2000) 21-28
19. Profenno L.A., and Faraone S.V. Diabetes and overweight associate with non-Apo-E4 genotype in an Alzheimer's disease population. Am J Med Genet B Neuropsychiatr Genet 147B (2008) 822-829
20. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 (2007) 559-575
21. Rankinen T., Zuberi A., Chagnon Y.C., Weisnagel S.J., Argyropoulos G., Walts B., et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring, Md.) 14 (2006) 529-644
22. Schneider W.J., Kovanen P.T., Brown M.S., Goldstein J.L., Utermann G., Weber W., et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 68 (1981) 1075-1085
23. Song Y., Stampfer M.J., and Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141 (2004) 137-147
24. Susce M.T., Villanueva N., Diaz F.J., and de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66 (2005) 167-173
25. Tang M., Dai Y., Huang Y., Cai X., Tian X., and Tu Z. The univariation and multiple linear regression analyses for seventeen SNPs in thirteen cardiovascular disease-predisposing genes and blood pressure in Chinese Han males. Clin Exp Hypertens 30 (2008) 648-661
26. Weisgraber K.H., Innerarity T.L., and Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257 (1982) 2518-2521
27. Xu M.Q., St Clair D., and He L. Meta-analysis of association between Apo-E epsilon4 allele and schizophrenia. Schizophr Res 84 (2006) 228-235
28. Yu C.E., Seltman H., Peskind E.R., Galloway N., Zhou P.X., Rosenthal E., et al. Comprehensive analysis of Apo-E and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 89 (2007) 655-665